Skip to content
10-Q

Quarterly Report

ENANTA PHARMACEUTICALS INC ENTA

0000950170-25-071340

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · May 1, 2025 21.38M sh
Cash And Equivalents Q2 2025 · Mar 31, 2025 $60.21M
Cash And Equivalents Q2 2025 · Sep 30, 2024 $37.23M
Current Liabilities Q2 2025 · Mar 31, 2025 $45.95M
Current Liabilities Q2 2025 · Sep 30, 2024 $57.54M
Total Liabilities Q2 2025 · Mar 31, 2025 $229.46M
Total Liabilities Q2 2025 · Sep 30, 2024 $247.84M
Current Assets Q2 2025 · Mar 31, 2025 $242.86M
Current Assets Q2 2025 · Sep 30, 2024 $299.85M
Total Assets Q2 2025 · Mar 31, 2025 $322.99M
Total Assets Q2 2025 · Sep 30, 2024 $376.65M
Net Income Q2 2025 · Sep 30, 2024 −$116.05M
Net Income Q2 2025 · Mar 31, 2024 −$31.16M
Net Income Q2 2025 · Mar 31, 2024 −$64.56M
Net Income Q2 2025 · Dec 31, 2023 −$33.41M
Shares Diluted Q2 2025 · Mar 31, 2024 21.17M sh
Shares Diluted Q2 2025 · Mar 31, 2024 21.13M sh
Capex Q2 2025 · Mar 31, 2024 $2.46M
Operating Cash Flow Q2 2025 · Mar 31, 2024 −$53.59M
Stockholders Equity Q2 2025 · Mar 31, 2024 $166.11M
Stockholders Equity Q2 2025 · Dec 31, 2023 $191.88M
Stockholders Equity Q2 2025 · Sep 30, 2023 $216.74M
Eps Diluted Q2 2025 · Mar 31, 2024 −$1.47
Eps Diluted Q2 2025 · Mar 31, 2024 −$3.06
Eps Basic Q2 2025 · Mar 31, 2024 −$1.47
Eps Basic Q2 2025 · Mar 31, 2024 −$3.06
Sga Expense Q2 2025 · Mar 31, 2024 $14.24M
Sga Expense Q2 2025 · Mar 31, 2024 $30.75M
Rd Expense Q2 2025 · Mar 31, 2024 $35.59M
Rd Expense Q2 2025 · Mar 31, 2024 $71.96M
Operating Income Q2 2025 · Mar 31, 2024 −$32.77M
Operating Income Q2 2025 · Mar 31, 2024 −$67.65M
Revenue Q2 2025 · Mar 31, 2024 $17.05M
Revenue Q2 2025 · Mar 31, 2024 $35.06M